Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
| Revenue (TTM) | $181.68M |
| Gross Profit (TTM) | $74.77M |
| EBITDA | $38.91M |
| Operating Margin | 15.40% |
| Return on Equity | 7.97% |
| Return on Assets | 4.19% |
| Revenue/Share (TTM) | $3.12 |
| Book Value | $4.50 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | 2.46 |
| EV/Revenue | 1.885 |
| EV/EBITDA | 8.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.80% |
| Shares Outstanding | $57.69M |
| Float | $31.27M |
| % Insiders | 7.20% |
| % Institutions | 47.90% |
Volatility is currently expanding
Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for undervalued stocks?
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced financial results for the three months and six months ended June 30, 2026.
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today announced that Chaime Orlev, its Chief Financial Officer (CFO), will transition out of his role to pursue other opportunities, effective December 31, 2026. Kamada has a search underway to identify a successor to Mr. Orlev, who has served as the Company's CFO since 2017. Mr. Orlev will provide transitional support to the new CFO to be appointed by Kamada.
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KMDA and any ticker you trade — then tracks every position and per-strategy win rate.
